Can I Take Folate With Evenity (Romosozumab)?

What Is Romosozumab and Why Does It Matter for Supplement Interactions?

Romosozumab (Evenity) is a monoclonal antibody that inhibits sclerostin, a protein produced by osteocytes that normally suppresses bone formation. By blocking sclerostin, romosozumab produces a dual effect: it increases bone mineral density (BMD) by stimulating osteoblasts and simultaneously reduces osteoclast-driven resorption. The FDA approved it in April 2019 for postmenopausal women with osteoporosis at high fracture risk. [1]

The drug is administered as two 105 mg subcutaneous injections (totaling 210 mg) once monthly for 12 months. After that course, patients transition to an antiresorptive agent such as denosumab or a bisphosphonate to consolidate gains. [2]

How Romosozumab Is Processed in the Body

Romosozumab follows the pharmacokinetic pathway typical of IgG2 monoclonal antibodies. It is not metabolized by cytochrome P450 enzymes, is not renally excreted in meaningful quantities, and does not bind plasma transport proteins in a way that would displace small-molecule nutrients. [3] Peak serum concentration occurs approximately 5 days after subcutaneous injection, with a mean half-life of about 6.4 days. [2]

Because the drug is degraded by standard proteolytic pathways into amino acids and small peptides, co-administration of water-soluble vitamins such as folate carries no realistic risk of altering romosozumab's plasma concentration, receptor binding, or clearance.

Why Supplements Are Still Worth Reviewing

Patients on Evenity are typically postmenopausal women over 60 who may also take anticonvulsants, methotrexate, sulfasalazine, or proton-pump inhibitors. Each of those drugs depletes folate through different mechanisms. [4] A clinician reviewing the full medication list is better positioned to identify whether supplemental folate is appropriate than any single-drug interaction checker.

Does Folate Interact With Romosozumab Pharmacokinetically?

No pharmacokinetic interaction between folate and romosozumab has been identified. The two substances operate through entirely separate biochemical pathways, and no published trial, case report, or FDA drug interaction study has documented a change in the absorption, distribution, metabolism, or elimination of either agent when taken together.

Folate's Absorption and Metabolism Pathway

Dietary folate and supplemental folic acid are absorbed in the proximal small intestine via the proton-coupled folate transporter (PCFT) and reduced folate carrier (RFC). [5] After absorption, folic acid is reduced to dihydrofolate and then to 5-methyltetrahydrofolate (5-MTHF) by dihydrofolate reductase and methylenetetrahydrofolate reductase (MTHFR). [6] None of these steps involve pathways through which a large monoclonal antibody could interfere.

Romosozumab, as a 188 kDa IgG2 protein, does not enter the intestinal lumen, does not bind PCFT or RFC, and has no known affinity for folate-metabolizing enzymes. [3]

Cytochrome P450 Non-Involvement

Because romosozumab bypasses hepatic CYP450 metabolism entirely, there is no risk of the enzyme induction or inhibition interactions seen with small-molecule drugs. Folate itself is not a CYP substrate or inducer at physiological doses. [4] The absence of a shared metabolic route is the primary reason the interaction risk is classified as negligible.

Does Folate Interact With Romosozumab Pharmacodynamically?

No pharmacodynamic conflict exists. Romosozumab acts on the Wnt/beta-catenin signaling pathway by neutralizing sclerostin. Folate supports one-carbon metabolism, DNA methylation, nucleotide synthesis, and homocysteine remethylation. [6] These pathways do not converge at a point where supplemental folate at standard doses (400 to 1,000 mcg daily) would amplify or blunt romosozumab's bone-forming effect.

Homocysteine, Bone Quality, and the Folate Connection

Elevated homocysteine is an independent risk factor for fracture. A meta-analysis of 14 prospective cohort studies (N=11,511) found that each 5 micromol/L increment in plasma homocysteine was associated with a 4% increase in hip fracture risk in women. [7] Folate, vitamin B12, and vitamin B6 are the primary nutrients that remethylate homocysteine back to methionine, keeping plasma homocysteine in the normal range (<10 micromol/L). [8]

This creates a theoretical additive benefit rather than a conflict: romosozumab stimulates new bone formation, while adequate folate status may help preserve collagen cross-linking quality by controlling homocysteine-mediated interference with lysyl oxidase. [9]

MTHFR Variants and Clinical Relevance for Osteoporosis Patients

The MTHFR C677T variant (homozygous TT genotype, present in roughly 10% of most populations) reduces enzyme activity by approximately 70%, leading to higher homocysteine and lower 5-MTHF. [10] Postmenopausal women with the TT genotype have measurably lower BMD at the femoral neck compared with CC carriers in several cohort studies. [11]

For these patients, ensuring adequate folate intake is directly relevant to bone health, independent of romosozumab. The B.PROOF trial (N=2,919) tested whether B-vitamin supplementation (400 mcg folic acid plus 500 mcg vitamin B12) reduced fracture incidence in older adults with elevated homocysteine. Although the primary fracture endpoint did not reach significance at 2 years (HR 0.84, 95% CI 0.58 to 1.22), a pre-specified subgroup with homocysteine above 26 micromol/L showed a 37% fracture reduction (P<0.05). [12]

Folate Depletion by Drugs Commonly Co-Prescribed With Romosozumab

Several medications frequently prescribed alongside Evenity deplete folate. Recognizing this overlap is where the clinical case for supplementation becomes strongest.

Anticonvulsants

Phenytoin, carbamazepine, valproate, and phenobarbital all reduce serum folate through induction of hepatic folate-catabolizing enzymes or by impairing intestinal absorption. [4] The American Academy of Neurology notes that patients on chronic anticonvulsant therapy should be assessed for folate deficiency, and supplementation at 1 to 5 mg daily is sometimes required depending on serum levels. [13] A postmenopausal woman taking phenytoin for a seizure disorder and romosozumab for osteoporosis has two independent reasons to monitor her folate status.

Methotrexate

Low-dose methotrexate (7.5 to 25 mg weekly for rheumatoid arthritis) inhibits dihydrofolate reductase, directly impairing folate activation. [14] Although methotrexate and romosozumab are rarely co-prescribed simultaneously, patients who previously used methotrexate may have residual folate depletion. The standard management is 1 to 5 mg folic acid daily on non-methotrexate days. [14]

Proton-Pump Inhibitors

Long-term PPI use reduces gastric acid, impairing the deconjugation of polyglutamate folate from food, which modestly decreases dietary folate absorption. [15] The effect is smaller than with anticonvulsants but relevant in patients already eating a folate-poor diet.

What Form of Folate Is Best for Patients on Evenity?

Standard folic acid (the synthetic oxidized form) requires conversion to 5-MTHF via MTHFR. Patients with the MTHFR C677T TT genotype convert folic acid poorly and may benefit from pre-methylated 5-methyltetrahydrofolate (5-MTHF, marketed as Quatrefolic or Metafolin) directly. [6]

For patients without known MTHFR variants, standard folic acid at 400 to 800 mcg daily covers dietary gaps and is the form used in the B.PROOF trial. [12] Folinic acid (leucovorin) is reserved for methotrexate toxicity rescue and is not appropriate for routine supplementation in the Evenity patient population.

The table below summarizes which folate form fits each clinical scenario for romosozumab patients:

| Clinical Scenario | Recommended Form | Dose Range | |---|---|---| | No known MTHFR variant, dietary gap only | Folic acid | 400 to 800 mcg daily | | MTHFR C677T homozygous (TT) | 5-MTHF (Quatrefolic/Metafolin) | 400 to 800 mcg daily | | Anticonvulsant co-use | Folic acid or 5-MTHF | 1 to 5 mg daily (clinician-directed) | | Post-methotrexate depletion | Folic acid | 1 to 5 mg daily on non-MTX days | | Elevated homocysteine (>10 micromol/L) | 5-MTHF plus B12 | 400 to 800 mcg 5-MTHF daily |

Monitoring Recommendations for Patients Taking Both

No special monitoring is required solely because folate and romosozumab are being co-administered. Monitoring needs arise from the patient's individual risk factors.

Baseline Labs to Consider

If a patient starting Evenity also has risk factors for folate insufficiency (anticonvulsant use, poor diet, MTHFR variant, prior methotrexate, alcohol use disorder, inflammatory bowel disease), baseline labs should include:

• Serum folate (reference: >3.0 ng/mL)
• Red blood cell folate (more reflective of tissue stores; reference: >140 ng/mL)
• Plasma homocysteine (target <10 micromol/L)
• Serum vitamin B12 (folate and B12 metabolism are linked; deficiency of B12 can mask folate status)

The NIH Office of Dietary Supplements recommends serum folate and RBC folate together when assessing deficiency because serum folate reflects recent intake while RBC folate reflects stores over the prior 2 to 3 months. [16]

Bone Density Monitoring on Romosozumab

The standard of care for romosozumab patients is dual-energy X-ray absorptiometry (DXA) at baseline and after the 12-month course to quantify BMD gains before transitioning to antiresorptive therapy. [2] Folate status does not alter DXA interpretation, but correcting elevated homocysteine before DXA may give a more accurate picture of true bone mineral quality versus quantity.

When to Involve a Specialist

Patients with homocysteine persistently above 15 micromol/L despite supplementation, or those with suspected MTHFR homozygosity plus a personal history of venous thromboembolism, should be referred to a hematologist or clinical geneticist for full methylation pathway assessment before adjusting folate doses further.

Safety Profile of Folate at Standard Doses

Folic acid is water-soluble. Excess is renally excreted. The tolerable upper intake level (UL) established by the National Academies of Medicine is 1,000 mcg daily for adults from fortified foods and supplements (not including naturally occurring food folate). [17] Doses at or below this level carry no credible toxicity signal in adults with normal renal function.

At doses above 1 mg daily, the primary clinical concern is masking vitamin B12 deficiency by correcting megaloblastic anemia without treating the neurological manifestations. [17] This is why co-supplementation with B12 (typically 500 to 1,000 mcg cyanocobalamin or methylcobalamin daily) is recommended whenever high-dose folate is used in older adults.

Romosozumab carries its own labeled cardiovascular warning. The FDA label states a higher rate of serious cardiovascular events (1.9% vs 1.4% placebo at 12 months in the FRAME trial, N=7,180) and contraindicates use in patients who have had a myocardial infarction or stroke within the past year. [1] This warning is unrelated to folate. Folate has no known effect on the cardiovascular adverse event profile of romosozumab.

Clinical Evidence on Romosozumab's Efficacy: Context for Supplement Decisions

Understanding how well romosozumab works puts supplement discussions in perspective.

FRAME Trial (N=7,180)

The FRAME trial randomized postmenopausal women with osteoporosis to romosozumab 210 mg monthly or placebo for 12 months, then transitioned both groups to denosumab for 12 months. At month 12, romosozumab reduced new vertebral fractures by 73% vs. Placebo (P<0.001). [18] BMD at the lumbar spine increased 13.3% in the romosozumab group vs. 0.0% in placebo.

ARCH Trial (N=4,093)

The ARCH trial compared romosozumab to alendronate in high-risk women. After 12 months of romosozumab followed by alendronate, the risk of a clinical fracture was 27% lower than in the group that received alendronate throughout (P<0.001). [19] The cardiovascular imbalance (2.5% vs 1.9%) that shaped the FDA black-box warning emerged primarily in the ARCH trial.

These efficacy figures establish that romosozumab is a high-impact treatment. Supplements that support bone quality, such as adequate calcium (1,000 to 1,200 mg daily from food and supplements), vitamin D (800 to 2,000 IU daily to maintain serum 25-OH-D above 30 ng/mL), and folate in deficient patients, are considered adjuncts rather than replacements. [20]

Practical Guidance: Taking Folate and Evenity Together

Timing and Administration

Romosozumab is given by subcutaneous injection at a clinic or self-administered at home once monthly. Because it is not an oral drug, no timing separation from oral folate is needed. There is no absorption window to protect, no gastric pH concern, and no competitive transporter to avoid.

Folate supplements are best taken with food to reduce any mild gastrointestinal discomfort, but this is a tolerability consideration, not a drug-interaction requirement.

Discussing With Your Prescriber

Before starting any supplement during an Evenity course, bring a complete list of all vitamins, minerals, and botanical supplements to your appointment. The prescribing clinician or pharmacist can cross-check for interactions with any other drugs in your regimen. The FDA MedWatch program accepts voluntary reports of unexpected supplement-drug interactions. [21]

The Endocrine Society's 2019 clinical practice guideline on osteoporosis in postmenopausal women states: "Adequate calcium and vitamin D intake should be ensured in all patients receiving pharmacologic treatment for osteoporosis." [20] The same principle extends to other micronutrients like folate: correct deficiencies, then maintain adequacy.

What the Evidence Does Not Support

No published randomized controlled trial has tested whether folate supplementation improves BMD outcomes specifically in romosozumab-treated patients. The interaction data reviewed here is mechanistic and observational. A direct co-administration trial would need to enroll hundreds of patients over 12 months to detect any additive BMD signal, and none is currently registered on ClinicalTrials.gov for this combination as of mid-2025.

Summary of the Interaction Classification

Folate and romosozumab have no identified pharmacokinetic or pharmacodynamic interaction. The clinical decision to supplement folate rests on the patient's individual folate status, MTHFR genotype, co-medications that deplete folate, homocysteine levels, and dietary intake. Order serum folate, RBC folate, plasma homocysteine, and B12 in any romosozumab patient with identifiable depletion risk factors before deciding on dose and form.